BCR-ABL Quantitative
RT-PCR Kit - Major, Minor & Micro
BCR-ABL Quantitative RT-PCR kit is a in-vitro multiplex, one-step, TaqMan probe-based quantitative assay for the specific detection and quantitation of Major, Minor and Micro BCR-ABL transcripts in the RNA/cDNA (template) extracted from EDTA whole blood or bone marrow aspirate of humans with Acute Lymphoblastic Leukemia (ALL) and Chronic Myeloid Leukemia (CML) symptoms. The kit can detect the Deep Molecular Response up to 5 Log reduction
SKU
-
100 Rxns : NBAQN22085
-
50 Rxns : NBAQN22085_01
-
20 Rxns : NBAQN22085_02
CDSCO
Approved
Features & Benefits:
-
IS quantitative, one-step RT PCR for quantifying the IS ratios of BCR-ABL Major (M-BCR) p210 transcript in CML patient samples.
-
Evaluates the molecular response up to 5 log reduction which is undetectable BCR-ABL1.
-
The reporting is based on European Treatment and Outcome Study (EUTOS) guidelines and European Leukemia Net (ELN) recommendations
-
The quantitation standards provided are with known copy numbers and are calibrated against WHO 1st International Genetic Reference Panel for the quantitation of BCR-ABL1 translocation (09/138) for assigning IS values to a measured level of BCR ABL/ABL %.
-
The minor BCR-ABL1 and micro BCR-ABL1 are reported in NCN%.
-
The kit supports reverse transcription. No additional cDNA steps are required.
-
High-Quality Takara Mastermix shows Increased Inhibitor Tolerance, Thermostability, and Reproducibility.
-
PCR run time: 90 Minutes
-
Works with RNA extracted from Whole Blood EDTA and Bone Marrow Aspirates
Storage & Precautions
-
Recommended Storage: -20°C
-
For Professional Use only.
-
Read user manual
Clinical Relevance
The BCR-ABL fusion gene, generated by the reciprocal translocation t(9;22)(q34;q11) forming the Philadelphia chromosome, encodes a constitutively active tyrosine kinase that drives the pathogenesis of Philadelphia chromosome–positive leukemias. Quantitative detection of the major BCR-ABL transcript (p210; e13a2/e14a2) is primarily used in Chronic Myeloid Leukemia (CML) for baseline assessment and longitudinal monitoring of disease burden, enabling evaluation of treatment response, detection of minimal residual disease (MRD), and identification of molecular relapse during or after tyrosine kinase inhibitor therapy. Quantification of the minor BCR-ABL transcript (p190; e1a2) is clinically relevant in Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) for monitoring therapeutic response and MRD, where transcript levels correlate with disease activity and prognosis.
The micro BCR-ABL transcript (p230; e19a2), though rare, may be quantified in patients with atypical or indolent CML variants to assess molecular disease burden and response to therapy. Overall, quantitative measurement of major, minor, and micro BCR-ABL transcripts provides critical information for treatment monitoring, response stratification, early detection of disease progression or relapse, and long-term clinical management of Philadelphia chromosome–positive leukemias.
